Lantheus Holdings, Inc.

LNTH

Nasdaq; healthcare; SIC 2835, In Vitro & In Vivo Diagnostic Substances; CIK 0001521036

A

strongest fifth of 369 graded peers in healthcare

rank 57 of 369; percentile 15.2; sampling error 2.5 points; lower is stronger

A B C D E

A, the bull



Scoreboard

Profitability	C percentile 43.6
Solvency	B/C percentile 39.9
Growth and financing	A/B percentile 19.8
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $2.2B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	9 of 14
Graded from	filings received through Feb 26, 2026 258 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$101.62 2026-11-10; market equity $6.6B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

We are the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. We classify our products into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Our Radiopharmaceutical Oncology product helps healthcare professionals ("HCPs") Find, Fight and Follow cancer. Our Precision Diagnostic products assist HCPs to Find and Follow diseases.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 43.6						
Gross profitability	42.3%	32.3%		29.4	365	2025-12-31
Return on invested capital	22.7%	9.3%		12.3	74	2025-12-31
Accruals ratio	(7.4%)	(6.6%)		52.3	800	2025-12-31
Gross margin stability, five years	7.3 pts	2.8 pts		80.5	242	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Solvency, sleeve percentile 39.9						
Twelve-month failure probability	not computable	0.08%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	4.61	(0.35)		19.9	745	2025-12-31
Net debt to EBITDA	not computable	1.82x				
required facts have no common fiscal period end						
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31						
Current ratio	2.70x	2.95x		60.0	826	2025-12-31
Growth and financing, sleeve percentile 19.8						
Revenue growth, three-year compound	18.1%	10.1%		34.5	412	2025-12-31
Free cash flow growth, three-year compound	not computable	11.0%				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31						
Reinvestment rate	not computable	37.1%				
latest aligned inputs end 2016-12-31; latest annual assets end 2025-12-31						
Asset growth, three years	19.0%	2.2%		22.1	694	2025-12-31
Net share issuance, one year	(5.7%)	2.5%		2.7	628	2026-02-23

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
52	Treace Medical Concepts, Inc. (TMCI)	13.9	A	
53	Ardelyx, Inc. (ARDX)	14.1	A	
54	Resmed Inc. (RMD)	14.4	A	fortress balance sheet
55	Janux Therapeutics, Inc. (JANX)	14.7	A	
56	Edwards Lifesciences Corp. (EW)	14.9	A	
57	Lantheus Holdings, Inc. (LNTH)	15.2	A	
58	Harrow, Inc. (HROW)	15.5	A	late filer
59	CareDx, Inc. (CDNA)	15.8	A	
60	Vertex Pharmaceuticals Inc. MA (VRTX)	16.0	A	
61	Ensign Group, Inc. (ENSG)	16.3	A	fortress balance sheet
62	Definium Therapeutics, Inc. (DFTX)	16.6	A	dilution

What the price implies

at the 2026-11-10 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	72.5%	(1.9%)	84
Distance from 52-week high	(8.4%)	(28.5%)	74
EBIT to enterprise value	4.8%	(1.6%)	79
Free cash flow yield	3.9%	(1.0%)	76
Book value to price	0.20	0.27	41
Sales to price	0.23	0.29	42

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Composite equity issuance, five years	(2.4%)	20.8%	25
Relative strength against the sector, log excess return	0.38	(0.19)	84

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 5 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$683.6M
Operating cash flow, four quarters	$409.5M
Months of runway	not finite
Days since last periodic filing	6 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$95.3M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$942.0M	2025-12-31	2026-02-26	10-K	26-073498
2	assets	us-gaap:Assets	$2.2B	2025-12-31	2026-02-26	10-K	26-073498
3	operating income	us-gaap:OperatingIncomeLoss	$310.8M	2025-12-31	2026-02-26	10-K	26-073498
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$313.8M	2025-12-31	2026-02-26	10-K	26-073498
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$80.2M	2025-12-31	2026-02-26	10-K	26-073498
6	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	$568.7M	2025-12-31	2026-02-26	10-K	26-073498
7	book equity	us-gaap:StockholdersEquity	$1.1B	2025-12-31	2026-02-26	10-K	26-073498
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$359.1M	2025-12-31	2026-02-26	10-K	26-073498
9	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	$565.3M	2024-12-31	2026-02-26	10-K	26-073498
10	book equity	us-gaap:StockholdersEquity	$1.1B	2024-12-31	2026-02-26	10-K	26-073498
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$912.8M	2024-12-31	2026-02-26	10-K	26-073498
12	net income	us-gaap:NetIncomeLoss	$233.6M	2025-12-31	2026-02-26	10-K	26-073498
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$390.1M	2025-12-31	2026-02-26	10-K	26-073498
14	assets	us-gaap:Assets	$2.0B	2024-12-31	2026-02-26	10-K	26-073498
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.5B	2025-12-31	2026-02-26	10-K	26-073498
16	gross profit	us-gaap:GrossProfit	$988.3M	2024-12-31	2026-02-26	10-K	26-073498
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.5B	2024-12-31	2026-02-26	10-K	26-073498
18	gross profit	us-gaap:GrossProfit	$709.5M	2023-12-31	2026-02-26	10-K	26-073498
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.3B	2023-12-31	2026-02-26	10-K	26-073498
20	gross profit	us-gaap:GrossProfit	$581.7M	2022-12-31	2025-02-26	10-K	25-007970
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$935.1M	2022-12-31	2025-02-26	10-K	25-007970
22	gross profit	us-gaap:GrossProfit	$187.7M	2021-12-31	2024-02-22	10-K	24-006158
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$425.2M	2021-12-31	2024-02-22	10-K	24-006158
24	current assets	us-gaap:AssetsCurrent	$900.0M	2025-12-31	2026-02-26	10-K	26-073498
25	current liabilities	us-gaap:LiabilitiesCurrent	$333.4M	2025-12-31	2026-02-26	10-K	26-073498
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$679.5M	2025-12-31	2026-02-26	10-K	26-073498
27	liabilities	us-gaap:Liabilities	$1.1B	2025-12-31	2026-02-26	10-K	26-073498
28	operating income	us-gaap:OperatingIncomeLoss	$364.6M	2023-12-31	2026-02-26	10-K	26-073498
29	interest expense	us-gaap:InterestExpense	$20.0M	2023-12-31	2024-02-22	10-K	24-006158

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$305.3M	2023-12-31	2026-02-26	10-K	26-073498
31	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$45.3M	2023-12-31	2024-02-22	10-K	24-006158
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$281.8M	2022-12-31	2025-02-26	10-K	25-007970
33	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$260.0M	2022-12-31	2024-02-22	10-K	24-006158
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$53.9M	2021-12-31	2024-02-22	10-K	24-006158
35	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$0	2021-12-31	2024-02-22	10-K	24-006158
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$16.4M	2020-12-31	2023-02-23	10-K	23-004698
37	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$0	2020-12-31	2023-02-23	10-K	23-004698
38	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$7.4M	2016-12-31	2019-02-20	10-K	19-001574
39	depreciation amortization	us-gaap:Depreciation	$800,000	2016-12-31	2017-02-23	10-K	17-053986
40	operating income	us-gaap:OperatingIncomeLoss	$56.6M	2016-12-31	2019-02-20	10-K	19-001574
41	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$28.3M	2016-12-31	2019-02-20	10-K	19-001574
42	income tax	us-gaap:IncomeTaxExpenseBenefit	$1.5M	2016-12-31	2019-02-20	10-K	19-001574
43	current assets	us-gaap:AssetsCurrent	$110.8M	2016-12-31	2018-02-26	10-K	18-002261
44	current liabilities	us-gaap:LiabilitiesCurrent	$43.8M	2016-12-31	2018-02-26	10-K	18-002261
45	current assets	us-gaap:AssetsCurrent	$90.0M	2015-12-31	2017-02-23	10-K	17-053986
46	current liabilities	us-gaap:LiabilitiesCurrent	$35.5M	2015-12-31	2017-02-23	10-K	17-053986
47	assets	us-gaap:Assets	$1.7B	2023-12-31	2025-02-26	10-K	25-007970
48	assets	us-gaap:Assets	$1.3B	2022-12-31	2024-02-22	10-K	24-006158
49	shares outstanding	dei:EntityCommonStockSharesOutstanding	64,605,894	2026-02-23	2026-02-26	10-K	26-073498
50	shares outstanding	dei:EntityCommonStockSharesOutstanding	68,476,575	2025-02-20	2025-02-26	10-K	25-007970

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.